BioStem (BSEM) Director Kenneth H. Warrington Jr. Exercises Options

What Happened

• Director Kenneth H. Warrington Jr. reported the exercise/conversion of 1,694 derivative securities into common stock on September 15, 2026. The filing shows an "acquired" entry and a matching "disposed" derivative entry for 1,694 shares at a reported price of $0.00 (total reported value $0). This was an exercise/conversion of derivative awards, not an open‑market purchase or sale of the common stock.

Key Details

• Transaction date: 2026-09-15; Form 4 filed: 2026-09-17 (timely).
• Transaction code: M (exercise or conversion of a derivative security).
• Shares involved: 1,694; reported exercise/conversion price: $0.00; reported total value: $0.
• Shares owned after transaction: not provided in the excerpt supplied.
• Footnotes from the filing:
  • F1: These options are fully vested and exercisable.
  • F2: Each restricted stock unit (RSU) represents a contingent right to receive one share.
  • F3: These RSUs vest in equal quarterly installments over three years from the grant date (Sept 15, 2024).
• No separate sale of underlying common shares is reported in this filing (i.e., no open‑market sale was shown).

Context

• Transaction code M indicates exercise or conversion of derivative securities (options or RSUs). The $0.00 exercise price and footnotes suggest the conversion involved vested awards (RSUs/options), but the filing shows conversion rather than a cash purchase or sale. Retail investors should treat this as an administrative conversion of awards into shares; it does not necessarily signal a buy or sell intent. Check future Form 4s or company disclosures if you want to see any later sale of the underlying shares.